Novo Nordisk (NVO) Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's (LLY) obesity pill, the expansion of the GLP-1 category, and the rollout of a new subscription model. He talks with Katie Greifeld for "The Close."

Bloomberg videos, provided by MT Newswires